During the peak of the coronavirus outbreak amid the second wave in India, there had been an unprecedented demand for Remdesivir - an antiviral medication for the treatment of patients. Due to shortage in the supply of Remdesivir, companies in the generic injectables market such as Hetero Drugs, an Indian pharmaceutical company and one of world’s largest producer of anti-retroviral drugs, released its generic form of Remdesivir called Covifor.
Manufacturers in the generic injectables market are becoming future-ready by maintaining adequate supply chains to prevent vulnerabilities caused by potential COVID-19-like situations. Drug firms including Zydus Cadila are observed to significantly reduce the price of its generic version of Remdesivir namely Remdac. Companies are taking the advantage of government programs and financial schemes offered by the BFSI sector to streamline their business activities as per the volatile market sentiments.
To know the scope of our report Get a Sample on Generic Injectables Market
Syringes are among the most difficult containers to inspect. With the largest vaccination effort in human history, challenges posed by syringe inspection become especially relevant while considering the ever-growing adoption of injectable drugs. These findings have led to the need of sophisticated inspection systems to help manufacturers address not only the coronavirus pandemic but also various other maladies.
While other containers such as cartridges, vials, and ampoules largely stand still and can enter the inspection process independently, syringes are typically carried via conveyor and then turned upside down. This has resulted in the need for robust inspection systems so that any hidden particles in the funnel can sink down into the liquid for increased inspection detectability.
Get a glimpse of the in-depth analysis through our Report Brochure
The global generic injectables market is projected to clock a CAGR of 12.3% during the forecast period. Biological E Limited - an Indian biotechnology and biopharmaceutical company based in Hyderabad, Telangana, is gaining recognition for broadening its portfolio in 20 routine and complex injectable products. In order to establish stable revenue streams, companies are tapping into regulated markets and exploring other markets to generate income sources.
There is a growing demand for specialty generic injectables packaged in glass vials. Express Pharma in associated with West Pharma recently conducted a webinar to understand why emerging generic injectable manufacturers need flexibility and simplicity when dealing with drug delivery and containment.
The generic injectables market is expected to cross US$ 307.7 Bn by 2031. The U.S. FDA (Food and Drug Administration) has approved the first generic of glucagon for injection USP for the treatment of severe hypoglycemia, which may occur in patients with diabetes mellitus. The drug has potentials as a diagnostic aid in the radiologic examination of the stomach, duodenum, small bowel, and colon in cases when diminished intestinal motility would be advantageous.
Companies in the generic injectables market are increasing their research to develop products meant for oncology and cardiology in order to expand their income sources.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Apart from drug launches and price cuts, stakeholders in the generic injectables market are conducting webinars to understand how manufacturers are combating COVID-19 with the help of flexibility and simplicity during drug containment and delivery. Sun Pharmaceutical Industries Limited— an Indian multinational pharmaceutical company headquartered in Mumbai, India, is being publicized for its high quality generic and branded injectables available at affordable costs worldwide. However, syringes are among the most difficult containers to inspect and require handling protocols that are different from other primary packaging types. Stakeholders in the generic injectables market should adopt sophisticated inspection systems for gentle handling of syringes and avoiding glass-to-glass contact, which mitigates the likelihood of cracks or breakage.
Generic Injectables Market – Segmentation
| Product Type |
|
| Application |
|
| Container Type |
|
| Route of Administration |
|
| Region |
|
Generic injectables market is expected to cross US$ 307.7 Bn by 2031
Generic injectables market is projected to clock a CAGR of 12.3% during 2021-2031
Generic injectables market is driven by rise in prevalence of various diseases and increase in demand for generic injectables
The large molecule injectables segment held major share of the global generic injectables market in 2020, and the trend is anticipated to continue during the forecast period
Key players in the market are Sanofi, Lupin Ltd., Biocon, Hikma Pharmaceuticals, Mylan N.V., Fresenius SE & Co
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Generic Injectables Market
4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Generic Injectables Market Analysis and Forecast, 2017–2031
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid /long term impact)
5.3. Regulatory Scenario, by Region/globally
5.4. Pipeline Analysis
5.5. Disease Prevalence & Incidence Rate globally with key countries
6. Global Generic Injectables Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Large Molecule Injectables
6.3.1.1. Monoclonal Antibodies (mAbs)
6.3.1.2. Insulin
6.3.1.3. Others
6.3.2. Small Molecule Injectables
6.4. Market Attractiveness Analysis, by Product Type
7. Global Generic Injectables Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Oncology
7.3.2. Infectious diseases
7.3.3. Cardiology
7.3.4. Diabetes
7.3.5. Immunology
7.3.6. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Generic Injectables Market Analysis and Forecast, by Container Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Container Type, 2017–2031
8.3.1. Vials
8.3.2. Premix
8.3.3. Prefilled Syringes
8.3.4. Ampoules
8.3.5. Others
8.4. Market Attractiveness Analysis, by Container Type
9. Global Generic Injectables Market Analysis and Forecast, by Route of Administration
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Route of Administration, 2017–2031
9.3.1. Intravenous
9.3.2. Intramuscular
9.3.3. Subcutaneous
9.3.4. Others
9.4. Market Attractiveness Analysis, by Route of Administration
10. Global Generic Injectables Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Generic Injectables Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017–2031
11.2.1. Large Molecule Injectables
11.2.1.1. Monoclonal Antibodies (mAbs)
11.2.1.2. Insulin
11.2.1.3. Others
11.2.2. Small Molecule Injectables
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Oncology
11.3.2. Infectious diseases
11.3.3. Cardiology
11.3.4. Diabetes
11.3.5. Immunology
11.3.6. Others
11.4. Market Value Forecast, by Container Type, 2017–2031
11.4.1. Vials
11.4.2. Premix
11.4.3. Prefilled Syringes
11.4.4. Ampoules
11.4.5. Others
11.5. Market Value Forecast, by Route of Administration, 2017–2031
11.5.1. Intravenous
11.5.2. Intramuscular
11.5.3. Subcutaneous
11.5.4. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Application
11.7.3. By Container Type
11.7.4. By Route of Administration
11.7.5. By Country
12. Europe Generic Injectables Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017–2031
12.2.1. Large Molecule Injectables
12.2.1.1. Monoclonal Antibodies (mAbs)
12.2.1.2. Insulin
12.2.1.3. Others
12.2.2. Small Molecule Injectables
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Oncology
12.3.2. Infectious diseases
12.3.3. Cardiology
12.3.4. Diabetes
12.3.5. Immunology
12.3.6. Others
12.4. Market Value Forecast, by Container Type, 2017–2031
12.4.1. Vials
12.4.2. Premix
12.4.3. Prefilled Syringes
12.4.4. Ampoules
12.4.5. Others
12.5. Market Value Forecast, by Route of Administration, 2017–2031
12.5.1. Intravenous
12.5.2. Intramuscular
12.5.3. Subcutaneous
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product Type
12.7.2. By Application
12.7.3. By Container Type
12.7.4. By Route of Administration
12.7.5. By Country/Sub-region
13. Asia Pacific Generic Injectables Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017–2031
13.2.1. Large Molecule Injectables
13.2.1.1. Monoclonal Antibodies (mAbs)
13.2.1.2. Insulin
13.2.1.3. Others
13.2.2. Small Molecule Injectables
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Oncology
13.3.2. Infectious diseases
13.3.3. Cardiology
13.3.4. Diabetes
13.3.5. Immunology
13.3.6. Others
13.4. Market Value Forecast, by Container Type, 2017–2031
13.4.1. Vials
13.4.2. Premix
13.4.3. Prefilled Syringes
13.4.4. Ampoules
13.4.5. Others
13.5. Market Value Forecast, by Route of Administration, 2017–2031
13.5.1. Intravenous
13.5.2. Intramuscular
13.5.3. Subcutaneous
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. India
13.6.3. Japan
13.6.4. Australia & New Zealand
13.7. Market Attractiveness Analysis
13.7.1. By Product Type
13.7.2. By Application
13.7.3. By Container Type
13.7.4. By Route of Administration
13.7.5. By Country/Sub-region
14. Latin America Generic Injectables Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2017–2031
14.2.1. Large Molecule Injectables
14.2.1.1. Monoclonal Antibodies (mAbs)
14.2.1.2. Insulin
14.2.1.3. Others
14.2.2. Small Molecule Injectables
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Oncology
14.3.2. Infectious diseases
14.3.3. Cardiology
14.3.4. Diabetes
14.3.5. Immunology
14.3.6. Others
14.4. Market Value Forecast, by Container Type, 2017–2031
14.4.1. Vials
14.4.2. Premix
14.4.3. Prefilled Syringes
14.4.4. Ampoules
14.4.5. Others
14.5. Market Value Forecast, by Route of Administration, 2017–2031
14.5.1. Intravenous
14.5.2. Intramuscular
14.5.3. Subcutaneous
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product Type
14.7.2. By Application
14.7.3. By Container Type
14.7.4. By Route of Administration
14.7.5. By Country/Sub-region
15. Middle East & Africa Generic Injectables Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Type, 2017–2031
15.2.1. Large Molecule Injectables
15.2.1.1. Monoclonal Antibodies (mAbs)
15.2.1.2. Insulin
15.2.1.3. Others
15.2.2. Small Molecule Injectables
15.3. Market Value Forecast, by Application, 2017–2031
15.3.1. Oncology
15.3.2. Infectious diseases
15.3.3. Cardiology
15.3.4. Diabetes
15.3.5. Immunology
15.3.6. Others
15.4. Market Value Forecast, by Container Type, 2017–2031
15.4.1. Vials
15.4.2. Premix
15.4.3. Prefilled Syringes
15.4.4. Ampoules
15.4.5. Others
15.5. Market Value Forecast, by Route of Administration, 2017–2031
15.5.1. Intravenous
15.5.2. Intramuscular
15.5.3. Subcutaneous
15.5.4. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product Type
15.7.2. By Application
15.7.3. By Container Type
15.7.4. By Route of Administration
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix
16.2. Market Share Analysis, by Company, 2020
16.3. Competitive Business Strategies
16.4. Company Profiles
16.4.1. AstraZeneca
16.4.1.1. Company Overview
16.4.1.2. Company Financials
16.4.1.3. Growth Strategies
16.4.1.4. SWOT Analysis
16.4.2. Baxter International, Inc.
16.4.2.1. Company Overview
16.4.2.2. Company Financials
16.4.2.3. Growth Strategies
16.4.2.4. SWOT Analysis
16.4.3. Biocon
16.4.3.1. Company Overview
16.4.3.2. Company Financials
16.4.3.3. Growth Strategies
16.4.3.4. SWOT Analysis
16.4.4. Fresenius SE & Co. KGaA
16.4.4.1. Company Overview
16.4.4.2. Company Financials
16.4.4.3. Growth Strategies
16.4.4.4. SWOT Analysis
16.4.5. GlaxoSmithKline plc
16.4.5.1. Company Overview
16.4.5.2. Company Financials
16.4.5.3. Growth Strategies
16.4.5.4. SWOT Analysis
16.4.6. Hikma Pharmaceuticals plc
16.4.6.1. Company Overview
16.4.6.2. Company Financials
16.4.6.3. Growth Strategies
16.4.6.4. SWOT Analysis
16.4.7. Johnson & Johnson Services, Inc.
16.4.7.1. Company Overview
16.4.7.2. Company Financials
16.4.7.3. Growth Strategies
16.4.7.4. SWOT Analysis
16.4.8. Lupin Ltd.
16.4.8.1. Company Overview
16.4.8.2. Company Financials
16.4.8.3. Growth Strategies
16.4.8.4. SWOT Analysis
16.4.9. Merck KGaA
16.4.9.1. Company Overview
16.4.9.2. Company Financials
16.4.9.3. Growth Strategies
16.4.9.4. SWOT Analysis
16.4.10. Mylan N.V.
16.4.10.1. Company Overview
16.4.10.2. Company Financials
16.4.10.3. Growth Strategies
16.4.10.4. SWOT Analysis
16.4.11. Novartis AG (Sandoz International GmbH)
16.4.11.1. Company Overview
16.4.11.2. Company Financials
16.4.11.3. Growth Strategies
16.4.11.4. SWOT Analysis
16.4.12. Pfizer, Inc.
16.4.12.1. Company Overview
16.4.12.2. Company Financials
16.4.12.3. Growth Strategies
16.4.12.4. SWOT Analysis
16.4.13. Piramal Pharma Solutions
16.4.13.1. Company Overview
16.4.13.2. Company Financials
16.4.13.3. Growth Strategies
16.4.13.4. SWOT Analysis
16.4.14. Sanofi
16.4.14.1. Company Overview
16.4.14.2. Company Financials
16.4.14.3. Growth Strategies
16.4.14.4. SWOT Analysis
16.4.15. Sun Pharmaceutical Industries Ltd.
16.4.15.1. Company Overview
16.4.15.2. Company Financials
16.4.15.3. Growth Strategies
16.4.15.4. SWOT Analysis
16.4.16. Teva Pharmaceutical Industries Ltd.
16.4.16.1. Company Overview
16.4.16.2. Company Financials
16.4.16.3. Growth Strategies
16.4.16.4. SWOT Analysis
List of Tables
Table 01: Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 02: Global Generic Injectables Market Value (US$ Mn) Forecast, by Large Molecule Injectables, 2017–2031
Table 03: Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 04: Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031
Table 05: Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 06: Global Generic Injectables Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 09: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 10: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 11: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031
Table 12: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration , 2017–2031
Table 13: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 15: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 16: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 17: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031
Table 18: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration , 2017–2031
Table 19: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 21: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 22: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 23: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031
Table 24: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration , 2017–2031
Table 25: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 27: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 28: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 29: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031
Table 30: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration , 2017–2031
Table 31: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 33: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 34: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 35: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031
Table 36: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
List of Figures
Figure 01: Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Generic Injectables Market Value Share, by Product Type, 2020
Figure 03: Global Generic Injectables Market Value Share, by Application, 2020
Figure 04: Global Generic Injectables Market Value Share, by Container Type, 2020
Figure 05: Global Generic Injectables Market Value Share, by Rout of Administration, 2020
Figure 06: Global Generic Injectables Market Value Share, by Region, 2020
Figure 07: Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 08: Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 09: Global Generic Injectables Market Revenue (US$ Mn), by Large Molecule Injectables, 2017–2031
Figure 10: Global Generic Injectables Market Revenue (US$ Mn), by Small Molecule Injectables, 2017–2031
Figure 11: Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031
Figure 12: Global Generic Injectables Market Attractiveness Analysis, by Application, 2021–2031
Figure 13: Global Generic Injectables Market Revenue (US$ Mn), by Oncology, 2017–2031
Figure 14: Global Generic Injectables Market Revenue (US$ Mn), by Infectious Disease, 2017–2031
Figure 15: Global Generic Injectables Market Revenue (US$ Mn), by Cardiology, 2017–2031
Figure 16: Global Generic Injectables Market Revenue (US$ Mn), by Diabetes, 2017–2031
Figure 17: Global Generic Injectables Market Revenue (US$ Mn), by Immunology, 2017–2031
Figure 18: Global Generic Injectables Market Revenue (US$ Mn), by Others, 2017–2031
Figure 19: Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031
Figure 20: Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031
Figure 21: Global Generic Injectables Market Value (US$ Mn), by Vials, 2017–2031
Figure 22: Global Generic Injectables Market Value (US$ Mn), by Premix, 2017–2031
Figure 23: Global Generic Injectables Market Value (US$ Mn), by Prefilled Syringes, 2017–2031
Figure 24: Global Generic Injectables Market Value (US$ Mn), by Ampoules, 2017–2031
Figure 25: Global Generic Injectables Market Value (US$ Mn), by Others, 2017–2031
Figure 26: Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 27: Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 28: Global Generic Injectables Market Value (US$ Mn), by Intravenous, 2017–2031
Figure 29: Global Generic Injectables Market Value (US$ Mn), by Intramuscular, 2017–2031
Figure 30: Global Generic Injectables Market Value (US$ Mn), by Subcutaneous, 2017–2031
Figure 31: Global Generic Injectables Market Value (US$ Mn), by Others, 2017–2031
Figure 32: Global Generic Injectables Market Value Share Analysis, by Region, 2020 and 2031
Figure 33: Global Generic Injectables Market Attractiveness Analysis, by Region, 2021–2031
Figure 34: North America Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031
Figure 35: North America Global Generic Injectables Market Value Share Analysis, by Country, 2020 and 2031
Figure 36: North America Global Generic Injectables Market Attractiveness Analysis, by Country, 2021–2031
Figure 37: North America Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 38: North America Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 39: North America Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031
Figure 40: North America Global Generic Injectables Market Attractiveness Analysis, by Material, 2021–2031
Figure 41: North America Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031
Figure 42: North America Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031
Figure 43: North America Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 44: North America Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 45: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031
Figure 46: Europe America Global Generic Injectables Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 47: Europe Global Generic Injectables Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 48: Europe Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 49: Europe Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 50: Europe Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031
Figure 51: Europe Global Generic Injectables Market Attractiveness Analysis, by Material, 2021–2031
Figure 52: Europe Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031
Figure 53: Europe Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031
Figure 54: Europe Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 55: Europe Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 56: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031
Figure 57: Asia Pacific Global Generic Injectables Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 58: Asia Pacific Global Generic Injectables Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 59: Asia Pacific Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 60: Asia Pacific Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 61: Asia Pacific Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031
Figure 62: Asia Pacific Global Generic Injectables Market Attractiveness Analysis, by Material, 2021–2031
Figure 63: Asia Pacific Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031
Figure 64: Asia Pacific Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031
Figure 65: Asia Pacific Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 66: Asia Pacific Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 67: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031
Figure 68: Latin America Global Generic Injectables Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 69: Latin America Global Generic Injectables Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 70: Latin America Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 71: Latin America Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 72: Latin America Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031
Figure 73: Latin America Global Generic Injectables Market Attractiveness Analysis, by Material, 2021–2031
Figure 74: Latin America Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031
Figure 75: Latin America Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031
Figure 76: Latin America Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 77: Latin America Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 78: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031
Figure 79: Middle East & Africa Global Generic Injectables Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 80: Middle East & Africa Global Generic Injectables Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 81: Middle East & Africa Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 82: Middle East & Africa Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 83: Middle East & Africa Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031
Figure 84: Middle East & Africa Global Generic Injectables Market Attractiveness Analysis, by Material, 2021–2031
Figure 85: Middle East & Africa Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031
Figure 86: Middle East & Africa Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031
Figure 87: Middle East & Africa Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 88: Middle East & Africa Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Generic Injectables Market Insights, 2021-2031
*86 figures and 60 tables includes